ZURA Zura Bio posts far wider Q4 2025 loss than consensus estimates sending its shares down 254 today Regeneron Pharmaceuticals REGN Unveils C5 Complement Pipeline Strategy But Execution Risks Cap NearTerm Upside RVSNW Rail signals focus on new North American rail client wins as its latest quarterly earnings metrics remain undisclosed